Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LCTX logo LCTX
Upturn stock ratingUpturn stock rating
LCTX logo

Lineage Cell Therapeutics Inc (LCTX)

Upturn stock ratingUpturn stock rating
$0.91
Last Close (24-hour delay)
Profit since last BUY51.67%
upturn advisory
Consider higher Upturn Star rating
BUY since 26 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: LCTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $3.92

1 Year Target Price $3.92

Analysts Price Target For last 52 week
$3.92Target price
Low$0.37
Current$0.91
high$1.15

Analysis of Past Performance

Type Stock
Historic Profit -15.83%
Avg. Invested days 19
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 213.56M USD
Price to earnings Ratio -
1Y Target Price 3.92
Price to earnings Ratio -
1Y Target Price 3.92
Volume (30-day avg) 7
Beta 1.52
52 Weeks Range 0.37 - 1.15
Updated Date 06/30/2025
52 Weeks Range 0.37 - 1.15
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.07

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -169.57%
Operating Margin (TTM) -433.09%

Management Effectiveness

Return on Assets (TTM) -12.1%
Return on Equity (TTM) -21.75%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 167897802
Price to Sales(TTM) 22.35
Enterprise Value 167897802
Price to Sales(TTM) 22.35
Enterprise Value to Revenue 17.57
Enterprise Value to EBITDA -8.84
Shares Outstanding 228356000
Shares Floating 177741118
Shares Outstanding 228356000
Shares Floating 177741118
Percent Insiders 0.42
Percent Institutions 47.94

Analyst Ratings

Rating 3
Target Price 3.92
Buy 2
Strong Buy 4
Buy 2
Strong Buy 4
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Lineage Cell Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Lineage Cell Therapeutics, Inc. was founded in 1990, initially focusing on a broad range of regenerative medicine technologies. Over time, the company narrowed its focus to cell therapies for degenerative diseases.

business area logo Core Business Areas

  • Opal: This program is an allogeneic cell therapy in Phase 2a clinical development for spinal cord injury. It aims to restore motor and sensory function by creating new synapses at the injury site.
  • OpRegen: This program is a retinal pigment epithelium (RPE) cell replacement therapy in Phase 2b clinical development for dry age-related macular degeneration (AMD) with geographic atrophy (GA). OpRegen is designed to replace cells lost to AMD, slowing or reversing vision loss.
  • VAC2: VAC2 is an allogeneic cancer immunotherapy in Phase 1/2a clinical development for non-small cell lung cancer (NSCLC). VAC2 consists of antigen-presenting cells that are engineered to stimulate the patientu2019s immune system to recognize and kill cancer cells.

leadership logo Leadership and Structure

Brian M. Culley is the CEO. The company has a board of directors and operates with a standard functional organizational structure, with departments for research and development, clinical trials, manufacturing, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Opal: Opal is in Phase 2a clinical trials for spinal cord injury. Market share data is not yet available as the product is not yet commercialized. Competitors include companies developing other spinal cord injury therapies, such as pharmacological interventions, neuromodulation devices and stem cell treatments.
  • OpRegen: OpRegen is in Phase 2b clinical trials for dry AMD with GA. Market share data is not yet available as the product is not yet commercialized. Competitors include Apellis (APLS) with Syfovre and Iveric Bio (ISEE), which was acquired by Astellas.
  • VAC2: VAC2 is in Phase 1/2a clinical development for NSCLC. Market share data is not yet available as the product is not yet commercialized. Competitors include pharmaceutical companies developing cancer immunotherapies, such as Merck (MRK) with Keytruda and Bristol Myers Squibb (BMY) with Opdivo.

Market Dynamics

industry overview logo Industry Overview

The regenerative medicine industry is growing, driven by advances in cell therapy and gene therapy. There is significant unmet need for treatments for degenerative diseases like AMD and spinal cord injury.

Positioning

Lineage Cell Therapeutics is positioned as a cell therapy company focused on developing allogeneic cell therapies for unmet medical needs. Its competitive advantage lies in its intellectual property and manufacturing expertise in cell therapies.

Total Addressable Market (TAM)

The total addressable market for cell therapies targeting AMD and spinal cord injury is estimated to be in the billions of dollars. Lineage is positioned to capture a portion of this market if its therapies are approved.

Upturn SWOT Analysis

Strengths

  • Proprietary cell therapy technology platform
  • Advanced clinical development programs
  • Experienced management team
  • Strong intellectual property portfolio
  • Allogeneic approach offers scalability.

Weaknesses

  • Clinical trial risk
  • Regulatory hurdles
  • Need for significant capital investment
  • Reliance on successful clinical outcomes
  • Competition from established pharmaceutical companies

Opportunities

  • Positive clinical trial results
  • Strategic partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Advancements in cell therapy manufacturing
  • Orphan drug designations

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from other cell therapy companies
  • Changes in healthcare reimbursement policies
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • APLS
  • BMY
  • MRK
  • ISEE

Competitive Landscape

Lineage Cell Therapeutics faces competition from both large pharmaceutical companies and smaller biotechnology companies. Its competitive advantage lies in its proprietary cell therapy technology platform.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by advancements in clinical development programs and strategic partnerships.

Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals. Analyst estimates vary widely, reflecting the uncertainty inherent in the biotechnology industry.

Recent Initiatives: Recent initiatives include advancing OpRegen and Opal through clinical trials and expanding partnerships.

Summary

Lineage Cell Therapeutics is a clinical-stage biotechnology company with promising cell therapy programs targeting unmet medical needs. The success of the company hinges on positive clinical trial results and regulatory approvals. However, the company faces significant challenges, including clinical trial risk, regulatory hurdles, and competition. They have a strong proprietary cell therapy technology platform and an experienced management team, setting them up for potential success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company press releases
  • SEC filings
  • Analyst reports
  • Company Website
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Lineage Cell Therapeutics Inc

Exchange NYSE MKT
Headquaters Carlsbad, CA, United States
IPO Launch date 1992-03-06
CEO, President & Director Mr. Brian M. Culley M.A., M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 70
Full time employees 70

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.